Published • loading... • Updated
UK Trials First Ebola Vaccine Using COVID-19 Platform
The Phase 1 study will test safety and immune response in 50 healthy adults, with larger trials planned if results are positive.
- On Monday, the University of Oxford launched the first human trial of a vaccine against Bundibugyo ebolavirus, seeking to combat the outbreak spreading in the Democratic Republic of Congo and Uganda.
- The Bundibugyo species has caused two previous outbreaks and currently spreads through Congo, where confirmed cases rose to 1,926, including 702 deaths, the country's public health institute said on Monday.
- Scientists at the Oxford Vaccine Group and Pandemic Sciences Institute developed the shot using the same viral vector platform as the AstraZeneca Covid vaccine; the Serum Institute of India stockpiled around 620,000 doses.
- The early-stage trial, known as BD-Ebov, will evaluate safety and immune response in 50 healthy adults aged 18 to 55, with The Coalition for Epidemic Preparedness Innovations investing up to $8.6 million.
- Chief investigator Dr. Katrina Pollock noted that Ebola species are "sisters rather than twins," requiring distinct vaccines; researchers plan further clinical studies in Uganda with year-long volunteer monitoring.
Insights by Ground AI
43 Articles
43 Articles
Coverage Details
Total News Sources43
Leaning Left8Leaning Right6Center11Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 32%
C 44%
R 24%
Factuality
To view factuality data please Upgrade to Premium
